EA
JAZZ icon

Emerald Advisers’s Jazz Pharmaceuticals JAZZ Stock Holding History

Emerald Advisers’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-3,597
Closed -$359K – 328
2020
Q1 		$359K Buy
+3,597
New +$465K 0.02% 183
2019
Q1 		– Sell
-2,517
Closed -$312K – 259
2018
Q4 		$312K Sell
2,517
-6,775
-73% -$1.01M 0.02% 215
2018
Q3 		$1.56M Sell
9,292
-316
-3% -$54.3K 0.06% 149
2018
Q2 		$1.66M Sell
9,608
-274
-3% -$44.8K 0.06% 148
2018
Q1 		$1.49M Buy
9,882
+679
+7% +$99.6K 0.06% 158
2017
Q4 		$1.24M Sell
9,203
-477
-5% -$66.2K 0.05% 168
2017
Q3 		$1.42M Buy
9,680
+1,442
+18% +$218K 0.06% 159
2017
Q2 		$1.28M Buy
+8,238
New +$1.26M 0.05% 163
2014
Q2 		– Sell
-6,970
Closed -$967K – 436
2014
Q1 		$967K Sell
6,970
-7,698
-52% -$1.16M 0.05% 251
2013
Q4 		$1.86M Sell
14,668
-153,586
-91% -$15.9M 0.1% 198
2013
Q3 		$15.5M Sell
168,254
-8,394
-5% -$677K 0.87% 26
2013
Q2 		$12.1M Buy
+176,648
New +$10.8M 0.74% 39

Other funds holding JAZZ

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Emerald Advisers's JAZZ Position: Q2 2020 in Review

Emerald Advisers sold out of Jazz Pharmaceuticals (JAZZ) in Q2 2020, closing a stake of 3,597 shares — an estimated $359K sold.

Emerald Advisers first reported a position in JAZZ in Q2 2013 and held it in 12 quarters. The position peaked at $15.5M in Q3 2013. 384 funds tracked by Wall St. Rank hold JAZZ as of Q2 2020.

  • Emerald Advisers reported no remaining Jazz Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
  • Emerald Advisers sold 3,597 Jazz Pharmaceuticals shares in Q2 2020, an estimated $359K.
  • Emerald Advisers first reported a position in Jazz Pharmaceuticals in Q2 2013 and held it in 12 quarters.
  • Emerald Advisers's Jazz Pharmaceuticals position peaked at $15.5M in Q3 2013.
  • 384 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2020.

Based on Emerald Advisers's 13F filing for Q2 2020, filed 28 Jul 2020.